Psoriasis News and Research

Latest Psoriasis News and Research

Global research links genes to five common, hard-to-treat inflammatory diseases

Global research links genes to five common, hard-to-treat inflammatory diseases

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Remicade co-developer funds new microscopy facility on Scripps Florida campus

Remicade co-developer funds new microscopy facility on Scripps Florida campus

Certain viral infections during pregnancy could cause behavioral changes in offspring

Certain viral infections during pregnancy could cause behavioral changes in offspring

Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

Age plays key role when it comes to patients' access to most efficient psoriasis treatment

Age plays key role when it comes to patients' access to most efficient psoriasis treatment

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Economic and racial barriers impact treatment of moderate to severe psoriasis

Economic and racial barriers impact treatment of moderate to severe psoriasis

Genetic information of patients with IBD could provide road map for more effective treatments

Genetic information of patients with IBD could provide road map for more effective treatments

Taking estriol along with conventional medications helps RRMS patients avoid relapses

Taking estriol along with conventional medications helps RRMS patients avoid relapses

New research reveals how gaps between gene interactions influence disease risk

New research reveals how gaps between gene interactions influence disease risk

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.